Soluble vascular endothelial growth factor receptor 2 and prognosis in patients with chronic heart failure
| Autor: | Yutaka Kajikawa, Akiyo Ninomiya, Hiromichi Wada, Masahiro Suzuki, Tsuyoshi Shinozaki, Mitsuru Abe, Koji Hasegawa, Akihiro Koike, Yujiro Ono, Yoshifumi Oishi, Yoichi Ajiro, Morihiro Matsuda, Tomomi Koizumi, Kazuro Yoshida, Masaharu Akao, Kazuhiko Kotani, Masatoshi Shimizu, Satoru Sakagami, Yukiko Morita, Moritake Iguchi, Toru Kato, Kazuteru Fujimoto, Prehosp-Chf Study Investigators, Junichi Funada, Takashi Takenaka, Toshihiro Nakamura, Kazuya Yonezawa |
|---|---|
| Rok vydání: | 2021 |
| Předmět: |
Male
Vascular Endothelial Growth Factor A medicine.medical_specialty medicine.drug_class Internal medicine Diabetes mellitus Original Research Articles Natriuretic peptide medicine Diseases of the circulatory (Cardiovascular) system Humans Prospective Studies Original Research Article Lymphangiogenesis Mortality Prospective cohort study Aged Aged 80 and over Heart Failure Ejection fraction business.industry Hazard ratio Endothelial Cells Atrial fibrillation Biomarker Middle Aged medicine.disease Prognosis Vascular Endothelial Growth Factor Receptor-2 Heart failure RC666-701 Cardiology Female Angiogenesis Cardiology and Cardiovascular Medicine business Mace |
| Zdroj: | ESC Heart Failure ESC Heart Failure, Vol 8, Iss 5, Pp 4187-4198 (2021) |
| ISSN: | 2055-5822 |
| Popis: | Aims Endothelial cell vascular endothelial growth factor receptor 2 (VEGFR‐2) plays a pivotal role in angiogenesis, which induces physiological cardiomyocyte hypertrophy via paracrine signalling between endothelial cells and cardiomyocytes. We investigated whether a decrease in circulating soluble VEGFR‐2 (sVEGFR‐2) levels is associated with poor prognosis in patients with chronic heart failure (HF). Methods and results We performed a multicentre prospective cohort study of 1024 consecutive patients with HF, who were admitted to hospitals due to acute decompensated HF and were stabilized after initial management. Serum levels of sVEGFR‐2 were measured at discharge. Patients were followed up over 2 years. The outcomes were cardiovascular death, all‐cause death, major adverse cardiovascular events (MACE) defined as a composite of cardiovascular death and HF hospitalization, and HF hospitalization. The mean age of the patients was 75.5 (standard deviation, 12.6) years, and 57% were male. Patients with lower sVEGFR‐2 levels were older and more likely to be female, and had greater proportions of atrial fibrillation and anaemia, and lower proportions of diabetes, dyslipidaemia, and HF with reduced ejection fraction ( |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|
Plný text